OAB0702 Overlapping significant life events are associated with HIV viral non-suppression among youth in clinics in rural East AfricaOral abstract session with live Q&AB51
OAB0703 Improving pediatric index testing: Data from 12 PEPFAR-supported countries in sub-Saharan AfricaOral abstract session with live Q&AB47
OAB0704 Biomarker assessment of infant adherence to isoniazid prophylaxis in a primary TB infection prevention trial in KenyaOral abstract session with live Q&AB55
OAB0705 Rates of cervical lesions by age and previous screening status and enhancing treatment among women living with HIV (WLHIV) in sub-Saharan Africa within the Go Further partnershipOral abstract session with live Q&AB14
OAB0706 Plasma exposure-viral load response analysis for dolutegravir in children with HIV-1: Results from IMPAACT P1093Oral abstract session with live Q&AB48
OABLB0101 Safety, pharmacokinetics and efficacy of low-dose E/C/F/TAF in virologically suppressed children '¥2 years old living with HIVOral abstract session with live Q&AB50
OABLB0102 Clinical outcomes by HIV serostatus, CD4 count, and viral suppression among people hospitalized with COVID-19 in the Bronx, New YorkOral abstract session with live Q&AB69
OABLB0103 The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trialOral abstract session with live Q&AB44
OABLB0104 Immunologic characteristics of acute COVID-19 in people with HIVOral abstract session with live Q&AB69
OABLB0105 Faster virological suppression with dolutegravir versus efavirenz in pregnancy does not lower the risk of HIV mother-to-child-transmission: A meta-analysis of 5 clinical trials in 1074 pregnant womenOral abstract session with live Q&AB44
seek-warrow-warrow-eseek-e101 - 110 of 2297 items